510 related articles for article (PubMed ID: 16533763)
1. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
[TBL] [Abstract][Full Text] [Related]
2. High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma.
Song YF; Xu R; Zhang XH; Chen BB; Chen Q; Chen YM; Xie Y
J Clin Pathol; 2006 Sep; 59(9):947-51. PubMed ID: 16489177
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells.
Kim TY; Jong HS; Song SH; Dimtchev A; Jeong SJ; Lee JW; Kim TY; Kim NK; Jung M; Bang YJ
Oncogene; 2003 Jun; 22(25):3943-51. PubMed ID: 12813468
[TBL] [Abstract][Full Text] [Related]
4. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
[TBL] [Abstract][Full Text] [Related]
5. Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
Das PM; Ramachandran K; Vanwert J; Ferdinand L; Gopisetty G; Reis IM; Singal R
Mol Cancer; 2006 Jul; 5():28. PubMed ID: 16848908
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
[TBL] [Abstract][Full Text] [Related]
7. Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas.
Chi SG; deVere White RW; Muenzer JT; Gumerlock PH
Clin Cancer Res; 1997 Oct; 3(10):1889-97. PubMed ID: 9815578
[TBL] [Abstract][Full Text] [Related]
8. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma.
Wong CM; Lee JM; Ching YP; Jin DY; Ng IO
Cancer Res; 2003 Nov; 63(22):7646-51. PubMed ID: 14633684
[TBL] [Abstract][Full Text] [Related]
9. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
[TBL] [Abstract][Full Text] [Related]
10. Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth.
Durkin ME; Ullmannova V; Guan M; Popescu NC
Oncogene; 2007 Jul; 26(31):4580-9. PubMed ID: 17297465
[TBL] [Abstract][Full Text] [Related]
11. DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas.
Yuan BZ; Jefferson AM; Baldwin KT; Thorgeirsson SS; Popescu NC; Reynolds SH
Oncogene; 2004 Feb; 23(7):1405-11. PubMed ID: 14661059
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers.
Yuan BZ; Durkin ME; Popescu NC
Cancer Genet Cytogenet; 2003 Jan; 140(2):113-7. PubMed ID: 12645648
[TBL] [Abstract][Full Text] [Related]
13. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
Enokida H; Shiina H; Igawa M; Ogishima T; Kawakami T; Bassett WW; Anast JW; Li LC; Urakami S; Terashima M; Verma M; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Cancer Res; 2004 Sep; 64(17):5956-62. PubMed ID: 15342374
[TBL] [Abstract][Full Text] [Related]
14. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
Shiina H; Breault JE; Basset WW; Enokida H; Urakami S; Li LC; Okino ST; Deguchi M; Kaneuchi M; Terashima M; Yoneda T; Shigeno K; Carroll PR; Igawa M; Dahiya R
Cancer Res; 2005 Mar; 65(6):2130-8. PubMed ID: 15781623
[TBL] [Abstract][Full Text] [Related]
15. Quantitative assessment of AKAP12 promoter methylation in human prostate cancer using methylation-sensitive high-resolution melting: correlation with Gleason score.
Liu W; Gong J; Hu J; Hu T; Sun Y; Du J; Sun C; Guan M; Jiang H; Lu Y
Urology; 2011 Apr; 77(4):1006.e1-7. PubMed ID: 21310466
[TBL] [Abstract][Full Text] [Related]
16. DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity.
Yuan BZ; Zhou X; Durkin ME; Zimonjic DB; Gumundsdottir K; Eyfjord JE; Thorgeirsson SS; Popescu NC
Oncogene; 2003 Jan; 22(3):445-50. PubMed ID: 12545165
[TBL] [Abstract][Full Text] [Related]
17. A quantitative promoter methylation profile of prostate cancer.
Jerónimo C; Henrique R; Hoque MO; Mambo E; Ribeiro FR; Varzim G; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Clin Cancer Res; 2004 Dec; 10(24):8472-8. PubMed ID: 15623627
[TBL] [Abstract][Full Text] [Related]
18. Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features.
Guan M; Xu C; Zhang F; Ye C
Int J Cancer; 2009 Jan; 124(1):88-94. PubMed ID: 18821581
[TBL] [Abstract][Full Text] [Related]
19. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
Sørensen KD; Borre M; Ørntoft TF; Dyrskjøt L; Tørring N
Int J Cancer; 2008 Feb; 122(3):509-19. PubMed ID: 17943724
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of EphA5 by promoter methylation in human prostate cancer.
Li S; Zhu Y; Ma C; Qiu Z; Zhang X; Kang Z; Wu Z; Wang H; Xu X; Zhang H; Ren G; Tang J; Li X; Guan M
BMC Cancer; 2015 Jan; 15():18. PubMed ID: 25609195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
